Objective:

To assess the interaction between Arylsulfatase B (ARSB) treatment and Pembrolizumab in improving specific therapeutic responses, such as apoptosis and tumor invasiveness, in melanoma.

Key Findings:

• ARSB treatment inhibited progression of subcutaneous and metastatic pulmonary melanomas.
• Combined treatment with ARSB and Pembrolizumab enhanced apoptosis and reduced invasiveness, indicating a synergistic effect.
• The combination therapy altered cytokine expression, which may play a role in the observed therapeutic benefits.

Interpretation:

The findings suggest that ARSB may enhance the effectiveness of Pembrolizumab in treating metastatic melanoma by targeting distinct mechanisms involved in tumor progression.

Limitations:

• The study was conducted in a mouse model, which may not fully replicate human responses, potentially limiting the applicability of the results.
• Further research is needed to confirm the findings in clinical settings to validate the therapeutic strategy.

Conclusion:

The combination of ARSB and Pembrolizumab may provide a promising therapeutic strategy for metastatic melanoma.